PURPOSE: The suitability of [18F]FDG, [18F]FLT, [18F]FET, and [18F]FCH as non-invasive positron emission tomography (PET) biomarkers for monitoring response to chemotherapy was analyzed in various experimental tumor models. PROCEDURES: Tracer uptake into three syngeneic rodent tumor models and ten human xenograft models was evaluated using semiquantitative analysis of small-animal PET data. Murine RIF-1 fibrosarcomas and [18F]FLT were selected to monitor the effects of the novel cytotoxic patupilone. RESULTS: Except [18F]FCH, all tracers provided good tumor visualization. Highest [18F]FDG uptake was identified in syngeneic tumors. Xenograft models, however, showed low [18F]FDG SUVs and were better visualized by [18F]FLT. Monitoring the effects of patupilone on [18F]FLT uptake in RIF-1 tumors revealed a significant decrease of tracer uptake after 24 h, which strongly negatively correlated with apoptosis. CONCLUSION: [18F]FLT PET of experimental tumors is a viable complement to [18F]FDG for preclinical drug development. [18F]FLT may be an excellent biomarker for patupilone-induced apoptosis.
PURPOSE: The suitability of [18F]FDG, [18F]FLT, [18F]FET, and [18F]FCH as non-invasive positron emission tomography (PET) biomarkers for monitoring response to chemotherapy was analyzed in various experimental tumor models. PROCEDURES: Tracer uptake into three syngeneic rodent tumor models and ten human xenograft models was evaluated using semiquantitative analysis of small-animal PET data. MurineRIF-1fibrosarcomas and [18F]FLT were selected to monitor the effects of the novel cytotoxic patupilone. RESULTS: Except [18F]FCH, all tracers provided good tumor visualization. Highest [18F]FDG uptake was identified in syngeneic tumors. Xenograft models, however, showed low [18F]FDG SUVs and were better visualized by [18F]FLT. Monitoring the effects of patupilone on [18F]FLT uptake in RIF-1 tumors revealed a significant decrease of tracer uptake after 24 h, which strongly negatively correlated with apoptosis. CONCLUSION: [18F]FLT PET of experimental tumors is a viable complement to [18F]FDG for preclinical drug development. [18F]FLT may be an excellent biomarker for patupilone-induced apoptosis.
Authors: Adriaan A Lammertsma; Corneline J Hoekstra; Giuseppe Giaccone; Otto S Hoekstra Journal: Eur J Nucl Med Mol Imaging Date: 2006-07 Impact factor: 9.236
Authors: N Shinoura; M Nishijima; T Hara; T Haisa; H Yamamoto; K Fujii; I Mitsui; N Kosaka; T Kondo; T Hara Journal: Radiology Date: 1997-02 Impact factor: 11.105
Authors: Barbara J Fueger; Johannes Czernin; Isabel Hildebrandt; Chris Tran; Benjamin S Halpern; David Stout; Michael E Phelps; Wolfgang A Weber Journal: J Nucl Med Date: 2006-06 Impact factor: 10.057
Authors: Michael Honer; Thomas Ebenhan; Peter R Allegrini; Simon M Ametamey; Mike Becquet; Catherine Cannet; Heidi A Lane; Terence M O'Reilly; Pius A Schubiger; Melanie Sticker-Jantscheff; Michael Stumm; Paul Mj McSheehy Journal: Transl Oncol Date: 2010-08-01 Impact factor: 4.243
Authors: Rogier P J Schroeder; W M van Weerden; E P Krenning; C H Bangma; S Berndsen; C H Grievink-de Ligt; H C Groen; S Reneman; E de Blois; W A P Breeman; M de Jong Journal: Eur J Nucl Med Mol Imaging Date: 2011-03-23 Impact factor: 9.236
Authors: Maria T Grinde; Nirma Skrbo; Siver A Moestue; Einar A Rødland; Eldrid Borgan; Alexandr Kristian; Beathe Sitter; Tone F Bathen; Anne-Lise Børresen-Dale; Gunhild M Mælandsmo; Olav Engebraaten; Therese Sørlie; Elisabetta Marangoni; Ingrid S Gribbestad Journal: Breast Cancer Res Date: 2014-01-21 Impact factor: 6.466
Authors: Emma J Haagensen; Huw D Thomas; Ian Wilson; Suzannah J Harnor; Sara L Payne; Tommy Rennison; Kate M Smith; Ross J Maxwell; David R Newell Journal: PLoS One Date: 2013-12-10 Impact factor: 3.240